Affordable Access

Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders.

Authors
  • Birgegård, Gunnar
  • Björkholm, Magnus
  • Kutti, Jack
  • Lärfars, Gerd
  • Löfvenberg, Eva
  • Markevärn, Berit
  • Merup, Mats
  • Palmblad, Jan
  • Mauritzson, Nils
  • Westin, Jan
  • Samuelsson, Jan
Type
Published Article
Journal
Haematologica
Publisher
Ferrata Storti Foundation
Publication Date
May 01, 2004
Volume
89
Issue
5
Pages
520–527
Identifiers
PMID: 15136214
Source
Medline
License
Unknown

Abstract

Side effects and toxic discontinuation rates were higher than in previous studies, probably because this is the first long-term prospective study of the feasibility and toxicity of anagrelide treatment. Nevertheless, anagrelide is a valuable alternative for treatment of thrombocythemia in myeloproliferative disorders for patients who tolerate the drug well.

Report this publication

Statistics

Seen <100 times